Tevogen Bio Holdings (NASDAQ:TVGN) shares are wobbling on Friday as the company is advancing its generics strategy through a signed letter of intent to evaluate a potential acquisition of Apozeal Pharmaceutical Inc.
The stock surged as high as $10.8 on Friday, before falling. With a market capitalization of $1.56 billion, the company’s institutional ownership is 2.4%, according to Benzinga Pro data.
Tevogen, on Thursday, announced that it has entered into a non-exclusive, non-binding Letter of Intent to explore a transaction with Apozeal, focused on developing cost-effective medicines.
The strategic move aims to bolster Tevogen’s generics platform, which is designed to enhance affordability and resilience in the U.S. pharmaceutical supply chain.
The potential acquisition could provide Tevogen with established assets and a growing pipeline, including FDA-approved ANDA assets.
Ryan Saadi, Tevogen’s CEO, emphasized that this initiative aligns with the company’s mission to support pharmaceutical affordability and domestic manufacturing.
Tevogen is also actively considering other transactions with a focus on life sciences-related businesses.
Tevogen approved a reverse stock split of 50 for 1, effective today.
In February, Tevogen Bio agreed to evaluate a potential transaction with Sciometrix Inc., a privately held healthcare technology and value-based care solutions provider.
Tevogen Technical Analysis
Currently, the stock is trading 34.5% below its 20-day simple moving average (SMA) and 58.6% below its 100-day SMA, highlighting significant weakness in its short- to medium-term performance.
Over the past 12 months, shares have decreased by 80.44% and are positioned closer to their 52-week lows than highs.
The RSI is at 21.46, indicating that the stock is in oversold territory, which may suggest a potential for a rebound. Meanwhile, the MACD shows a value of -1.4156, with a signal line at -0.9987, indicating bearish momentum as the MACD remains below the signal line.
The combination of an oversold RSI and bearish MACD suggests mixed momentum, indicating that while the stock is oversold, bearish pressure persists.
- Key Resistance: $15.00
- Key Support: $7.00
Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for Tevogen Bio Holdings, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Weak (Score: 0.27) — Stock is underperforming the broader market.
The Verdict: Tevogen Bio Holdings’s Benzinga Edge signal reveals a classic ‘High-Flyer’ setup. While the weak momentum score indicates underperformance, the company’s strategic moves in the generics space could present future opportunities.
TVGN Price Action: Tevogen Bio Holdings shares were down 15.41% at $6.56 at the time of publication on Friday. The stock is trading at a new 52-week low, according to Benzinga Pro data.
Image via Shutterstock
